Clinical trials: Relapsing-Remitting
Relapsing-Remitting Multiple Sclerosis
Clinical Disease Activity With Long Term Natalizumab Treatment
The primary objective of the study is to retrospectively investigate the proportion of participants free of new or enlarging fluid-attenuated inversion recovery (FLAIR) lesions over time in approximately 300 Relapsing-Remitting…
- Trial name
- NCT02677077
- Testing
- natalizumab
- Where
- 4 sites in Belgium, Czechia
- Volunteers
- 277 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
This is an open-label, randomized, multicenter, comparative, and parallel-group study comparing the therapeutic effects of two interferon-beta-1a regimens in relapsing-remitting multiple sclerosis (MS).
- Trial name
- NCT00292266
- Testing
- Rebif®, Avonex®
- Volunteers
- 677 people
- Sponsor
- EMD Serono
Relapsing-Remitting Multiple Sclerosis
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
The purpose of this study is to determine if medication designed to improve memory will help patients with Multiple Sclerosis (MS) who are experiencing memory problems using fMRI to track brain activity.
- Trial name
- NCT00315367
- Testing
- Donepezil HCI (drug)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Neurognostics
Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis
The purpose of this study is to further evaluate the safety and efficacy of Tovaxin in the treatment of relapsing forms of multiple sclerosis.
- Trial name
- OLTERMS (NCT00595920)
- Testing
- Tovaxin
- Where
- 27 sites in United States
- Volunteers
- 116 people
- Sponsor
- Opexa Therapeutics, Inc.
Multiple Sclerosis, Relapsing Remitting
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients
This study is observational, non-controlled, multicentric and prospective, without experimental intervention or control. As part of the usual management of the subjects, scales will be used for the assessment of the spasticity…
- Trial name
- NCT01080040
- Where
- Argentina
- Volunteers
- 150 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-Remitting Multiple Sclerosis (RRMS)
A Study for Tysabri Participant Preference
The primary objective of this study is to collect, evaluate and compare data on participant preference between subcutaneous (SC) and intravenous (IV) natalizumab.
- Trial name
- NCT05304520
- Testing
- Natalizumab
- Where
- 40 sites in Germany
- Volunteers
- 318 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT06408259
- Testing
- Ozanimod, Fingolimod
- Where
- 33 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- Bristol-Myers Squibb
Multiple Sclerosis
Efficacy and Safety of GTR in Comparison to Copaxone®
The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis
- Trial name
- GATE (NCT01489254)
- Testing
- Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®)
- Where
- 133 sites in United States, Belarus and 17 more
- Volunteers
- 794 people
- Sponsor
- Synthon BV
Relapsing-Remitting Multiple Sclerosis
Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt
The purpose of this observational study is to evaluate the Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients with Relapsing-Remitting Multiple Sclerosis in Egypt
- Trial name
- NCT05423769
- Testing
- Fingolimod
- Where
- 2 sites in Egypt
- Volunteers
- 30 people
- Sponsor
- Hikma Pharmaceuticals LLC
Multiple Sclerosis
ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon
Study to evaluate efficacy of fingolimod in patients with neutralizing antibodies over 12 months
- Trial name
- ENGYNE (NCT01621269)
- Testing
- Fingolimod
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
The purpose of this prospective, multicenter, open-label, efficacy, and safety study is to assess the efficacy and safety of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who have had a suboptimal…
- Trial name
- NCT02861014
- Testing
- Ocrelizumab
- Where
- 163 sites in Australia, Belgium and 15 more
- Volunteers
- 681 people
- Sponsor
- Hoffmann-La Roche
Relapsing Remitting Multiple Sclerosis
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)
This is a Phase 2, randomized, rater-blinded, 5-arm, parallel-group trial that will test 4 doses of plovamer acetate against the active comparator Copaxone in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT01963611
- Testing
- Plovamer acetate 0.5 milligram (mg), Copaxone 20 mg, Plovamer acetate 3 mg
- Where
- 118 sites in United States, Bulgaria and 15 more
- Volunteers
- 255 people
- Sponsor
- EMD Serono
Relapsing-Remitting Multiple Sclerosis (RRMS)
Brimonidine Tartrate for the Treatment of Injection Related Erythema
The primary objective of this study is to evaluate the Injection Related Erythema (IRE) mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel (placebo).
- Trial name
- BRITE (NCT02568111)
- Testing
- peginterferon beta-1a, brimonidine tartrate, Vehicle Gel
- Sponsor
- Biogen
Multiple Sclerosis
A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS.
- Trial name
- NCT00097188
- Testing
- rituximab
- Where
- 31 sites in United States
- Volunteers
- 104 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis, Relapsing-Remitting
A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment.
- Trial name
- NCT02587806
- Testing
- Autologous Bone Marrow-Derived Mononuclear Stem Cells, Liberation therapy
- Where
- 2 sites in India, Trinidad and Tobago
- Volunteers
- 69 people
- Sponsor
- Novo Cellular Medicine Institute LLP
Relapsing Remitting Multiple Sclerosis
An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease
This is a multinational, multicenter, randomized, double-blind, parallel-group active extension of LAQ/5062 study (NCT00349193), assessing the tolerability, safety and efficacy of two doses (0.3 mg and 0.6 mg) of laquinimod…
- Trial name
- NCT00745615
- Testing
- Laquinimod
- Where
- 45 sites in Czechia, Germany and 7 more
- Volunteers
- 257 people
- Sponsor
- Teva Pharmaceutical Industries, Ltd.
Multiple Sclerosis
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
This study is to find out if there is any benefit to adding Simvastatin to Interferon-beta-1a in patients with Multiple Sclerosis.
- Trial name
- SIMCOMBIN (NCT00492765)
- Testing
- Interferon-beta-1a, Simvastatin
- Where
- Denmark
- Volunteers
- 380 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
- Trial name
- ENSURE-2 (NCT05201638)
- Testing
- IMU-838 tablets
- Where
- 101 sites in United States, Armenia and 12 more
- Volunteers
- 1,100 people
- Sponsor
- Immunic AG
Relapsing-remitting Multiple Sclerosis (RRMS)
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
This is a randomized, controlled, multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of rocbrutinib (LP-168), an oral BTK inhibitor, in subjects with paramagnetic rim lesion (PRL)-positive…
- Trial name
- NCT07776743
- Testing
- Rocbrutinib, Dimethyl Fumarate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Relapsing Remitting Multiple Sclerosis
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
The purpose of this study is to evaluate the change in patient-reported treatment satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs.
- Trial name
- EPOC (NCT01317004)
- Testing
- Fingolimod, Standard MS DMT
- Where
- 17 sites in Italy
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals